共 51 条
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know
被引:2
作者:
Opitz, Isabelle
[1
]
Bueno, Raphael
[2
]
Lim, Eric
[3
,4
]
Pass, Harvey
[5
]
Pastorino, Ugo
[6
]
Boeri, Mattia
[7
]
Rocco, Gaetano
[8
]
机构:
[1] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland
[2] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA
[3] Univ London Imperial Coll Sci Technol & Med, London, England
[4] Royal Brompton Hosp, Acad Div Thorac Surg, London SW3 6LY, England
[5] NYU, Langone Med Ctr, Dept Cardiothorac Surg, New York, NY USA
[6] Ist Nazl Tumori, Div Thorac Surg, I-20133 Milan, Italy
[7] Ist Nazl Tumori, Tumor Genom Unit, I-20133 Milan, Italy
[8] Fdn G Pascale, IRCCS, Inst Nazl Tumori, Dept Thorac Surg & Oncol, Naples, Italy
关键词:
Malignant pleural mesothelioma;
Lung cancer;
Biomarker;
microRNAs;
Genomic sequencing;
SERUM OSTEOPONTIN LEVELS;
PLASMA OSTEOPONTIN;
DIAGNOSIS;
MICRORNAS;
DNA;
EXPRESSION;
BIOMARKERS;
SURVIVAL;
QUANTIFICATION;
VALIDATION;
D O I:
10.1093/ejcts/ezu048
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Today, molecular-profile-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons' professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.
引用
收藏
页码:602 / 606
页数:5
相关论文